DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for malignant epithelial tumor of ovary — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant epithelial tumor of ovary maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant epithelial tumor of ovary is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
poly(ADP-ribose) polymerase family member 3 (PARP3) — PARP3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-oxo-3,4-dihydroquinazolin-2-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4GV2 · 1.8 Å · ligand 3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1R)-1-(pyridin-2-yl)ethyl]propanamide (5ME). Experimental structure, not a prediction.
What the evidence adds up to
Ovarian epithelial malignant tumours are a heterogeneous group of neoplasms classified by histopathologic type and grade, ranging from benign and borderline to malignant histotypes with distinct molecular and immunophenotypic features. The three main categories of ovarian tumours are epithelial, germ cell, and sex-cord stromal tumours. Most malignant epithelial cases are high-grade serous, clear cell, and endometrioid carcinomas; borderline serous and mucinous tumours of intestinal type are less common. Uncommon or rare epithelial tumours include borderline and malignant Brenner tumours, the recently described mesonephric-like carcinoma of the ovary, and primary ovarian neuroendocrine tumours.
Immunohistochemistry and molecular testing help pathologists decipher the significant heterogeneity of epithelial ovarian carcinomas. A better understanding of the molecular basis of these carcinomas is described as the first step in the development of targeted therapies. Recent advances in classification include updated histopathological, immunophenotypic and molecular diagnostic criteria, with attention to terminology discrepancies and diagnostic challenges.
These changes are said to provide a better understanding of the nature of ovarian tumours and to lead to more efficient therapeutic management. No concrete numbers on survival, response rates, or sample sizes are reported in any of the abstracts. No specific drug, targeted therapy, or treatment outcome is mentioned.
What is still missing is any clinical trial data testing a specific drug or intervention in patients with these tumours. The abstracts are reviews and classifications, not experimental results. Money for prospective trials, a trial design that accounts for the heterogeneity of histotypes, and patient stratification by molecular subtype are all absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
癌症：英文版 · 2015 · 75 citations · open access
Pathobiology of ovarian carcinomas
AbstractOvarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future.
Diagnostic histopathology · 2020 · 2 citations · open access
Uncommon ovarian epithelial tumours
AbstractEpithelial ovarian tumours represent the most common type of ovarian tumour. Most of malignant cases represent high-grade serous, clear cell and endometrioid carcinomas; borderline serous and mucinous tumours of intestinal type are less common. This review focuses on the uncommon or rare epithelial tumours of the ovary which include borderline and malignant Brenner tumours, the recently-described mesonephric-like carcinoma of the ovary, and primary ovarian neuroendocrine tumours, with emphasis on helpful and diagnostic features.
IntechOpen eBooks · 2022 · 0 citations · open access
Recent Advances in Classification and Histopathological Diagnosis of Ovarian Epithelial Malignant Tumours
AbstractOvarian tumours are a heterogeneous group of neoplasms classified based on histopathologic type and grade of differentiation. They comprise a broad range of tumours from benign and borderline to malignant histotypes characterised by different histopathological, immunophenotypic and molecular features. The purpose of this chapter is to present an overview of the recent advances in the ovarian epithelial malignant tumours classification along with the histopathological, immunophenotypic and molecular diagnostic criteria highlighting areas of terminology discrepancies or changes and diagnostic challenges. These changes provide a better understanding of the ovarian tumours nature and lead to a more efficient therapeutic management of these pathological entities.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
